Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL72604 | 0.70 | CTSK (0.37) | CTSKDDB1CRBNMEN1NPC1 | |
| SCHEMBL932957 | 0.69 | GRIN2B (0.43) | CTSKMEN1KMT2A | |
| SCHEMBL20722072 | 0.67 | KDM4E (0.30) | CTSKMEN1KMT2A | |
| SCHEMBL5163254 | 0.66 | MEN1 (0.33) | CTSKMEN1NPC1RAB9AKMT2A | |
| SCHEMBL18571277 | 0.65 | CTSK (0.33) | CTSKMEN1KMT2A | |
| SCHEMBL18571347 | 0.65 | CTSK (0.33) | CTSKMEN1KMT2A | |
| SCHEMBL28509736 | 0.65 | DRD2 (0.36) | CTSKMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28832612 | 0.65 | GRIN2B (0.40) | CTSKMEN1KMT2A | |
| SCHEMBL21810904 | 0.64 | LMNA (0.32) | CTSK | |
| SCHEMBL19022230 | 0.64 | ITGB1 (0.32) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | CTSK 4186/4885DDB1 3788/4885CRBN 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.